This study is the first to demonstrate that treating nasal congestion with xylometazoline hydrochloride 0.1% during the common cold positively impacts QoL factors relevant to daily living in a real-life setting. Findings from this study suggest that xylometazoline hydrochloride 0.1% usage during the common cold helps improve breathing, may have positive implications on sleep quality, general performance, and enable individuals to feel better during an episode of the common cold. The results presented in this real-world study provide a broader perspective on symptom relief during the common cold and the positive impact this has on QoL, which may inform healthcare decision making for patients and providers alike.